We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Extends PDUFA Date for Biogen’s MS Treatment BG-12 to Late March
FDA Extends PDUFA Date for Biogen’s MS Treatment BG-12 to Late March
October 26, 2012
The FDA has extended the PDUFA date for Biogen Idec’s multiple sclerosis (MS) treatment BG-12 by three months to March 28, 2013.